Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy
Brief Summary: The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with Everolimus (Afinitor) on progression-free survival (PFS) and overall survival (OS) in subjects with advanced renal cell cancer that has progressed after prior VEGFR tyrosine kinase inhibitor therapy.


Options:
A: Arm Label: Alternating regimen; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Everolimus | Arm Label: Sequential treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pazopanib, Drug: Everolimus | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Sequential treatment | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Sequential treatment | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Alternating regimen
B: Arm Label: bevacizumab, RAD001 (everolimus); Type: EXPERIMENTAL; Interventions: Drug: RAD001(everolimus), Drug: bevacizumab | Arm Label: bevacizumab, interferon alfa-2a (IFN); Type: ACTIVE_COMPARATOR; Interventions: Drug: interferon alfa-2a, Drug: bevacizumab | Intervention Type: DRUG; Name: RAD001(everolimus); Assigned to Arm(s): bevacizumab, RAD001 (everolimus) | Intervention Type: DRUG; Name: interferon alfa-2a; Assigned to Arm(s): bevacizumab, interferon alfa-2a (IFN) | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab, RAD001 (everolimus), bevacizumab, interferon alfa-2a (IFN)
C: Arm Label: Cabozantinib (XL184); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib tablets | Arm Label: Everolimus (Afinitor); Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus (Afinitor) tablets | Intervention Type: DRUG; Name: Cabozantinib tablets; Assigned to Arm(s): Cabozantinib (XL184) | Intervention Type: DRUG; Name: Everolimus (Afinitor) tablets; Assigned to Arm(s): Everolimus (Afinitor)
D: Arm Label: Atezolizumab and Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab | Arm Label: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab, Drug: Sunitinib | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody; Assigned to Arm(s): Atezolizumab, Atezolizumab and Bevacizumab, Sunitinib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Atezolizumab, Atezolizumab and Bevacizumab, Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib

Answer: C